Endometriosis Australia calls for urgent action to protect access to essential treatment following Zoladex withdrawal 

Endometriosis Australia is deeply concerned by the announcement that Zoladex® (goserelin 3.6 mg) will be withdrawn from the Australian market later this year. 

For thousands of Australian women living with endometriosis and adenomyosis, Zoladex has been an important part of the therapeutic toolkit for managing severe symptoms and improving quality of life. While it is not a cure, it has provided meaningful relief for many women whose treatment options are already limited. 

Endometriosis Australia is concerned not only about the loss of a medication, but about the message this sends to women living with chronic pelvic pain. 

Women with endometriosis already face an average diagnostic delay of many years, repeated surgery, significant out-of-pocket costs and substantial impacts on education, employment and fertility. Removing an established treatment option risks further narrowing an already constrained pathway to care. 

“Women with endometriosis already fight hard enough to access care. Australia cannot afford to make that journey even harder by allowing essential treatment options to quietly disappear.” 

A/Prof. Anusch Yazdani, Endometriosis Australia Medical Director   

Importantly, this decision is understood to be a commercial one rather than one related to the safety or effectiveness of the medication. Women currently receiving treatment should not stop therapy without discussing their individual circumstances with their treating specialist. 

While many patients may be able to transition safely to alternative therapies, treatment decisions for endometriosis are highly individualised, and for some women, changing therapy may involve new side effects, altered efficacy, or disruption to carefully planned fertility or surgical management. 

Australia has made significant progress in recognising endometriosis as a major public health issue through the National Action Plan for Endometriosis, but the loss of established treatment options without adequate replacement strategies leaves a critical, foundational gap in the management options for Australian women. 

Endometriosis Australia will continue to advocate for patients, work with clinicians and policymakers, and support women navigating this change.